Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Dr. Nimish Patel's main research interest involves evaluating clinical outcomes associated with anti-infective medications. Dr. Patel's research encompasses three domains: 1) comparative safety and effectiveness of antimicrobials in real-world settings, 2) predictors and outcomes of patients with contraindicated drug-drug interactions and 3) pharmacoeconomic strategies of emerging antimicrobial agents that result in a cost savings relative to existing medications associated with a high frequency of costly toxicities or prolonged hospitalization. Dr. Patel's clinical areas of expertise are treatment of hospitalized patients with infectious diseases, pharmacokinetic monitoring of antimicrobials, antibiotic stewardship, HIV consult service and hepatitis C. Some of his current research projects include: real-world safety and effectiveness of fluoroquinolones versus ceftriaxone/azithromycin for patients with community acquired pneumonia, incidence and predictors of outcomes among patients with diabetic foot infections, and effect of exogenous hormones on renal function and drug concentrations in transgender patients using pre-exposure prophylaxis
Education: Pharm.D., Albany College of Pharmacy & Health Sciences (2006); Pharmacy Residency in HIV Pharmacotherapy, University of Toronto/University Health Network – Toronto General Hospital Immunodeficiency Clinic and McGill University Health Centre – Montreal Chest Institute (2007); Fellowship in Infectious Diseases Outcomes Research, Albany College of Pharmacy & Health Sciences (2010); M.S. Epidemiology, University at Albany – State University of New York (2010); American Academy of HIV Medicine Pharmacist Credentialing (2012); Ph.D. Epidemiology, University at Albany – State University of New York (2014).
Awards and Honors: Faculty Preceptor of the Year at ACPHS. (2012); Teacher of the Year at ACPHS (2012), Society of Infectious Diseases Pharmacists (SIDP) Young Investigator Research Award (2014); Janis V. Giorgi Memorial Award – California HIV/AIDS Research Program (2019).
Leadership Experience: Journal reviewer for J of Antimicrob Chemother, Diag Microbiol and Infect Dis, Infect Dis and Therapy, Antimicrob Agents and Chemother, Pharmacotherapy, Open Forum and Infect Dis and Am J Health-Sys Pharm
- Therapeutics IV (SPPS 212D)
- Drug Information (SPPS 220)
- Real world effectiveness and safety of antimicrobials for vancomycin-resistant Enterococcal bacteremia.
- Comparative effectiveness of fidaxomicin versus oral vancomycin for C. difficile infections
- Predictors of drug-drug interactions among Veterans living with HIV and hepatitis C
- Lodise TP, Henriksen AS, Hadley T, Patel N. (2021). US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales. Open Forum Infect Dis. 15;8(10)
- Patel N. et al (2021). Comparative effectiveness of early-targeted use of fidaxomicin versus oral vancomycin among hospitalized veterans' affairs patients with infections due to Clostridioides difficile. Pharmacotherapy 41(2):212-219.
- Maskarinec SA et al (2020). Positive follow-up blood cultures identify high mortality risk among patients with Gram-negative bacteraemia. Clin Microbiol Infect. 26(7):904-910.
- Ahmed A et al (2019). Comparing Drug Interaction Frequencies of Various Hepatitis C Treatment Regimens among Monoinfected Patients. Ann Hepatol. (4):601-606.
- Sangiovanni R et al (2019). Relationship between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations among HIV-infected Patients Initiating Combination Antiretroviral Therapy. AIDS Res Hum Retroviruses. (5):430-433.
- Patel N et al. (2018) Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. Clin Drug Investig. (10):935-943.
- Bidell MR et al. (2018). Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother. 3(10):2643-2651.
- Patel N et al. (2018). Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database. Am J Health Syst Pharm. 75(15):1132-1139.
- Yager JL et al (2017). Relationship Between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications Among Veterans' Affairs Patients with Human Immunodeficiency Virus. AIDS Patient Care STDS. (9):370-376.
- Britt NS et al (2017). Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. Clin Infect Dis. 64(5):605-613.
- Jakeman B et al. (2017). Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients. Ann Pharmacother. (5):365-372
- Investigator-initiated research grants assessing real-world safety and effectiveness of anti-infective agents used among Veterans Affairs patients with infectious diseases
- Investigator-initiated research grants assessing frequency and predictors of contraindicated drug-drug interactions among patients with HIV and hepatitis C